At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 143 enrolled
Drug / intervention
Antithrombin-III +9 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL): a First-in-men Study
In Brief
A Phase 2 clinical trial evaluating Antithrombin-III, Infliximab, and 8 other interventions for Reperfusion Injury. Completed, enrolled 143 participants across 1 site.
Detailed Summary
The purpose of this study is to establish the effectiveness of the combined drug approach (anti-thrombin III, infliximab, apotransferrin, human recombinant erythropoietin beta, C1-inhibitor, glutathione, alfa-tocopherol, melatonin and epoprostenol)aimed to reduce ischemia-reperfusion injury during liver transplantation in eligible recipients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsReperfusion Injury
CountriesBelgium
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedSep 2014
Primary CompletionFeb 2019
Study CompletionAug 2019
TodayJul 2026
First PostedSep 26, 2014
Enrollment StartSep 1, 2014
Primary CompletionFeb 1, 2019
Study CompletionAug 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 11.8 years ago
Interventions
Antithrombin-IIIdrug
Infliximabdrug
Apotransferrindrug
Human recombinant erythropoietindrug
C1-Inhibitordrug
Glutathionedrug
Alfa-tocopheroldrug
Melatonindrug
Epoprostenoldrug
Sodium chloride solutiondrug